ELI LILLY AND COMPANY Net Income (Loss) Available to Common Stockholders, Basic
ELI LILLY AND COMPANY (LLY) reported Net Income (Loss) Available to Common Stockholders, Basic of $4.09 billion for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-21.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2013-02-21
- ELI LILLY AND COMPANY net income (loss) available to common stockholders, basic for fiscal 2012 was $4.09B, a 5.96% decline from fiscal 2011.
- ELI LILLY AND COMPANY net income (loss) available to common stockholders, basic for fiscal 2011 was $4.35B, a 14.24% decline from fiscal 2010.
- ELI LILLY AND COMPANY net income (loss) available to common stockholders, basic for fiscal 2010 was $5.07B, a 17.11% increase from fiscal 2009.
- ELI LILLY AND COMPANY net income (loss) available to common stockholders, basic for fiscal 2009 was $4.33B.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|
| 2012-12-31 | $4.09B 10-K · filed 2013-02-21 |
| 2011-12-31 | $4.35B 10-K · filed 2013-02-21 |
| 2010-12-31 | $5.07B 10-K · filed 2013-02-21 |
| 2009-12-31 | $4.33B 10-K · filed 2012-02-24 |
| 2008-12-31 | -$2.07B 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |